Thierry Trenque
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Thierry Trenque has a total of 119 co-authors. Here are the top co-authors by number of shared publications:
- Brahim Azzouz
Université de Reims Champagne-Ardenne, VIEFRA, CHU de Reims, Centre Régional de Pharmacovigilance de Reims, Reims, France
6 shared publications Emmanuelle Herlem
Regional Centre of Pharmacovigilance and Pharmacoepidemiology Reims University Hospital 51100 Reims France
5 shared publicationsPaul de Boissieu
Centre régional de pharmacovigilance et de pharmaco-épidémiologie de Champagne-Ardenne, CHU de Reims, 51092 Reims, France; EA 3797, faculté de médecine, université de Reims Champagne-Ardenne, 51100 Reims, France
5 shared publicationsAgathe Trenque
Reims University Hospitals, Regional Centre for Pharmacovigilance and Pharmacoepidemiology, 51092 Reims, France
4 shared publicationsAurore Morel
Regional Centre of Pharmacovigilance and Pharmacoepidemiology Reims University Hospital Reims France
4 shared publicationsH. Millart
Laboratoire de Pharmacologie‐Toxicologie, CHU, Reims
4 shared publications
Latest Publications
- Open Access
- 28 August 2023
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 90 (8) , 1873-1879
Drug‐induced Sweet's syndrome: A case/non‐case study in the French pharmacovigilance database
Aims: Sweet's syndrome is an acute febrile neutrophilic dermatosis first described in 1964 by Robert Douglas Sweet. The pathophysiological mechanism is not fully established; however, several cases of Sweet's syndrome have been reported following drug administration.Methods: To investigate the existence of pharmacovigilance signals between drugs and the occurrence of Sweet's syndrome, we performed a case/non‐case study on reports of ‘acute febrile neutrophilic dermatosis’ registered in the French pharmacovigilance database. Reporting odds ratio (ROR) with its 95% confidence interval were calculated.Results: Amongthe 994 789 reports recorded in the database, 136 were Sweet's syndrome, of which 50.7% were men and the median age was 59 years (range 15–91). A total of 224 drugs were mentioned as suspects: 21.0% were antibacterials, 19.2% were antineoplastics and 12.1% were immunosuppressants. Median time to onset from drug initiation to the development of Sweet's syndrome was 15 days (range 1–1095). The highest RORs were observed with bortezomib (74.04 [40.8–134.2]), azacitidine (72.14 [29.4–176.9]), perfilgrastim (67.05 [21.2–211.6]), azathioprine (55.46 [34.8–88.4]) and bendamustine (35.84 [11.4–112.8]).Conclusions: Pharmacovigilance signals have been observed between the occurrence of Sweet's syndrome and colony‐stimulating factors, immunosuppressants, antineoplastics and antibiotics. Clinicians should be aware of the potential associations with these drugs and should be encouraged to report any case of drug‐induced Sweet's syndrome.
- 28 August 2023
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 90 (8) , 1873-1879
Open AccessDrug‐induced Sweet's syndrome: A case/non‐case study in the French pharmacovigilance database
Aims: Sweet's syndrome is an acute febrile neutrophilic dermatosis first described in 1964 by Robert Douglas Sweet. The pathophysiological mechanism is not fully established; however, several cases of Sweet's syndrome have been reported following drug administration.Methods: To investigate the existence of pharmacovigilance signals between drugs and the occurrence of Sweet's syndrome, we performed a case/non‐case study on reports of ‘acute febrile neutrophilic dermatosis’ registered in the French pharmacovigilance database. Reporting odds ratio (ROR) with its 95% confidence interval were calculated.Results: Amongthe 994 789 reports recorded in the database, 136 were Sweet's syndrome, of which 50.7% were men and the median age was 59 years (range 15–91). A total of 224 drugs were mentioned as suspects: 21.0% were antibacterials, 19.2% were antineoplastics and 12.1% were immunosuppressants. Median time to onset from drug initiation to the development of Sweet's syndrome was 15 days (range 1–1095). The highest RORs were observed with bortezomib (74.04 [40.8–134.2]), azacitidine (72.14 [29.4–176.9]), perfilgrastim (67.05 [21.2–211.6]), azathioprine (55.46 [34.8–88.4]) and bendamustine (35.84 [11.4–112.8]).Conclusions: Pharmacovigilance signals have been observed between the occurrence of Sweet's syndrome and colony‐stimulating factors, immunosuppressants, antineoplastics and antibiotics. Clinicians should be aware of the potential associations with these drugs and should be encouraged to report any case of drug‐induced Sweet's syndrome.
- 6 April 2022
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 88 (8) , 3813-3818
Psoriasis risk after beta‐blocker exposure: Description of a pharmacovigilance signal
Aim: We aimed to investigate French pharmacovigilance data. The objective was to characterize psoriatic conditions that occurred after beta‐blocker (BB) exposure and bring to light a possible pharmacovigilance signal.Methods: Spontaneous reports of psoriatic conditions recorded in the French National Pharmacovigilance Database (FPVD) between 1985 and 2019 were extracted. We performed a retrospective, descriptive analysis of reports linked to BB exposure. Association between psoriasis risk and BB exposure was assessed using a case/noncase study.Results: Two hundred and twenty‐five reports of psoriatic conditions after BB exposure were recorded in the FPVD during the study period. Both cardioselective and noncardioselective, topical and systemic BBs are involved. Therapeutic indication of BB was mainly hypertension. Mean time to onset was 5 months and outcome was favourable in 68% after BB discontinuation. These features were concordant with those of literature reports. The reporting odds ratio (ROR) was 8.95 (95% confidence interval 7.75‐10.33).Conclusion: We highlighted a statistically significant disproportionality which constitutes a pharmacovigilance signal. Psoriasis risk with BBs is a class effect. Increasing surveillance during the first year of BB exposure is needed.
- 6 April 2022
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 88 (8) , 3813-3818
Psoriasis risk after beta‐blocker exposure: Description of a pharmacovigilance signal
Aim: We aimed to investigate French pharmacovigilance data. The objective was to characterize psoriatic conditions that occurred after beta‐blocker (BB) exposure and bring to light a possible pharmacovigilance signal.Methods: Spontaneous reports of psoriatic conditions recorded in the French National Pharmacovigilance Database (FPVD) between 1985 and 2019 were extracted. We performed a retrospective, descriptive analysis of reports linked to BB exposure. Association between psoriasis risk and BB exposure was assessed using a case/noncase study.Results: Two hundred and twenty‐five reports of psoriatic conditions after BB exposure were recorded in the FPVD during the study period. Both cardioselective and noncardioselective, topical and systemic BBs are involved. Therapeutic indication of BB was mainly hypertension. Mean time to onset was 5 months and outcome was favourable in 68% after BB discontinuation. These features were concordant with those of literature reports. The reporting odds ratio (ROR) was 8.95 (95% confidence interval 7.75‐10.33).Conclusion: We highlighted a statistically significant disproportionality which constitutes a pharmacovigilance signal. Psoriasis risk with BBs is a class effect. Increasing surveillance during the first year of BB exposure is needed.
- 6 January 2022
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 78 (4) , 687-690
Immune-mediated necrotizing myopathy with pembrolizumab: a specific neuromuscular entity
Purpose Pembrolizumab is a humanized monoclonal antibody that binds to the programmed cell-death protein-1 (PD-1) on immune T-cells, thus blocking PD-1 activity. Pembrolizumab is indicated for the treatment of advanced melanoma, metastatic non-small-cell lung cancer, and head and neck squamous cell carcinoma. However, it is associated with immune-related adverse events. Methods We investigated the association between pembrolizumab and immune-mediated necrotizing myopathy (IMNM). We analyzed reports in the World Health Organization’s global individual case safety report database, Vigibase, up to January 2020 with the MedDRA lower level term “IMNM.” The association between exposure to pembrolizumab and occurrence of the adverse event was estimated by disproportionality analysis. The reporting odds ratio (ROR) was calculated with 95% confidence intervals (CIs). We analyzed the criteria of diagnosis of the adverse reaction. Results Five-hundred sixty-seven notifications were identified as IMNM of which 14 with pembrolizumab. The ROR was 17.59 (95% CI: 9.4–32.9). Conclusion The diagnosis of IMNM does not always take into account recent criteria for the diagnosis of this pathology. This study highlights the existence of a signal, as well as the need for collaboration between oncologists and neurologists for these neurological pathologies.
- 6 January 2022
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 78 (4) , 687-690
Immune-mediated necrotizing myopathy with pembrolizumab: a specific neuromuscular entity
Purpose Pembrolizumab is a humanized monoclonal antibody that binds to the programmed cell-death protein-1 (PD-1) on immune T-cells, thus blocking PD-1 activity. Pembrolizumab is indicated for the treatment of advanced melanoma, metastatic non-small-cell lung cancer, and head and neck squamous cell carcinoma. However, it is associated with immune-related adverse events. Methods We investigated the association between pembrolizumab and immune-mediated necrotizing myopathy (IMNM). We analyzed reports in the World Health Organization’s global individual case safety report database, Vigibase, up to January 2020 with the MedDRA lower level term “IMNM.” The association between exposure to pembrolizumab and occurrence of the adverse event was estimated by disproportionality analysis. The reporting odds ratio (ROR) was calculated with 95% confidence intervals (CIs). We analyzed the criteria of diagnosis of the adverse reaction. Results Five-hundred sixty-seven notifications were identified as IMNM of which 14 with pembrolizumab. The ROR was 17.59 (95% CI: 9.4–32.9). Conclusion The diagnosis of IMNM does not always take into account recent criteria for the diagnosis of this pathology. This study highlights the existence of a signal, as well as the need for collaboration between oncologists and neurologists for these neurological pathologies.
- 27 December 2020
- Published by Taylor & Francis in Expert Opinion on Drug Safety
- Vol. 20 (3) , 373-378
Drug induced stuttering: pharmacovigilance data
Background: Stuttering is a speech disorder characterized by poor fluency of speech despite the speech production organs being normal. Numerous factors contribute to stuttering, and it may also be an iatrogenic effect of certain drugs. The aim of this study was to investigate the association between stuttering and drug exposure. Research design and methods: We investigated the association between drugs and stuttering. We analyzed reports in the World Health Organization global individual case safety reports database (Vigibase) up to 31 May 2020 with the MedDRA lower level terms ‘stutter’ and ‘stuttering.’ The association between a drug and the occurrence of the adverse drug reaction was estimated by disproportionality analysis. Reporting odds ratios (ROR) were calculated with 95% confidence intervals. Results: In total, 724 notifications were identified using the MedDRA terms selected. The main drugs implicated were methylphenidate (ROR = 19.58; 95% CI: 13.3–28.8), topiramate (ROR = 12.5; 95% CI: 7.1–22.1), olanzapine (ROR = 12; 95% CI: 8–17.9) and golimumab (ROR = 10.2; 95% CI: 5.5–19.1). Conclusions: When stuttering occurs in a patient treated by drugs affecting neurotransmission, a drug-induced origin of the stutter should be considered.
- 27 December 2020
- Published by Taylor & Francis in Expert Opinion on Drug Safety
- Vol. 20 (3) , 373-378
Drug induced stuttering: pharmacovigilance data
Background: Stuttering is a speech disorder characterized by poor fluency of speech despite the speech production organs being normal. Numerous factors contribute to stuttering, and it may also be an iatrogenic effect of certain drugs. The aim of this study was to investigate the association between stuttering and drug exposure. Research design and methods: We investigated the association between drugs and stuttering. We analyzed reports in the World Health Organization global individual case safety reports database (Vigibase) up to 31 May 2020 with the MedDRA lower level terms ‘stutter’ and ‘stuttering.’ The association between a drug and the occurrence of the adverse drug reaction was estimated by disproportionality analysis. Reporting odds ratios (ROR) were calculated with 95% confidence intervals. Results: In total, 724 notifications were identified using the MedDRA terms selected. The main drugs implicated were methylphenidate (ROR = 19.58; 95% CI: 13.3–28.8), topiramate (ROR = 12.5; 95% CI: 7.1–22.1), olanzapine (ROR = 12; 95% CI: 8–17.9) and golimumab (ROR = 10.2; 95% CI: 5.5–19.1). Conclusions: When stuttering occurs in a patient treated by drugs affecting neurotransmission, a drug-induced origin of the stutter should be considered.
- 30 April 2020
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 86 (11) , 2256-2265
Amoxicillin‐induced crystal nephropathy: A nationwide French pharmacovigilance databases study
Aims: Amoxicillin (AMX)‐induced crystal nephropathy (AICN) is a rarely reported adverse drug reaction (ADR) but its increase has been recently reported in the Paris area. Our aim was to investigate the incidence, characteristics and outcome of AICN in France.Methods: Retrospective analysis of all AICN cases reported to the French National Pharmacovigilance Database and the Marketing Authorization Holders Pharmacovigilance Database. AICN notification rate was compared to intravenous AMX and AMX–clavulanate sales.Results: In total, 101 AICN cases were included. Intravenous AMX/AMX–clavulanate was prescribed as surgical prophylaxis (32 surgical patients) or to treat infection (69 medical patients). AKI KDIGO stage 3 was observed in 70 patients and 24/70 patients required renal replacement therapy and/or intensive care unit admission. The annual notification rate of AICN was increased by a factor of 13 since 2010 (6 [0;7] and 77 [24;111] cases per 100 000 patient‐years of exposure, before and after 2010 respectively; P < .001). In surgical patients, the increase in AICN has been reported since 2010 and was mainly related to inadequate AMX administration. In medical patients, the increase in AICN was observed since 2014. After 2014, medical patients were older (67 [42;77] vs 74 years [64;84] respectively; P < .05) and were treated more frequently for endocarditis (0/20 vs 15/49 respectively; P < .01). A contributing factor was observed or suspected in 62 patients.Conclusion: AICN is a severe ADR that dramatically increased in France since 2010. Assessment of AICN contributing factors and AMX drug monitoring in patients receiving high dose of AMX could reduce the risk of AICN.
- 30 April 2020
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 86 (11) , 2256-2265
Amoxicillin‐induced crystal nephropathy: A nationwide French pharmacovigilance databases study
Aims: Amoxicillin (AMX)‐induced crystal nephropathy (AICN) is a rarely reported adverse drug reaction (ADR) but its increase has been recently reported in the Paris area. Our aim was to investigate the incidence, characteristics and outcome of AICN in France.Methods: Retrospective analysis of all AICN cases reported to the French National Pharmacovigilance Database and the Marketing Authorization Holders Pharmacovigilance Database. AICN notification rate was compared to intravenous AMX and AMX–clavulanate sales.Results: In total, 101 AICN cases were included. Intravenous AMX/AMX–clavulanate was prescribed as surgical prophylaxis (32 surgical patients) or to treat infection (69 medical patients). AKI KDIGO stage 3 was observed in 70 patients and 24/70 patients required renal replacement therapy and/or intensive care unit admission. The annual notification rate of AICN was increased by a factor of 13 since 2010 (6 [0;7] and 77 [24;111] cases per 100 000 patient‐years of exposure, before and after 2010 respectively; P < .001). In surgical patients, the increase in AICN has been reported since 2010 and was mainly related to inadequate AMX administration. In medical patients, the increase in AICN was observed since 2014. After 2014, medical patients were older (67 [42;77] vs 74 years [64;84] respectively; P < .05) and were treated more frequently for endocarditis (0/20 vs 15/49 respectively; P < .01). A contributing factor was observed or suspected in 62 patients.Conclusion: AICN is a severe ADR that dramatically increased in France since 2010. Assessment of AICN contributing factors and AMX drug monitoring in patients receiving high dose of AMX could reduce the risk of AICN.
- Open Access
- 16 August 2019
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 85 (11) , 2634-2637
Methylphenidate and stuttering
Methylphenidate (MPH) is a piperidine similar to amphetamines, and is indicated for attention deficit hyperactivity disorder. Studies concerning stuttering occurring with MPH are contradictory. We investigated the association between MPH and stuttering. We analysed reports in the World Health Organization global individual case safety reports database, Vigibase, up to 31 December 2018, with the MedDRA preferred term “dysphemia” and the lower level terms “stutter” and “stuttering”. The association between exposure to MPH and occurrence of the adverse drug reaction was estimated by disproportionality analysis. Reporting odds ratios (RORs) were calculated with 95% confidence intervals (CIs). In total, 2975 cases of dysphemia were reported, of which 46 reports were associated with MPH. For the Preferred Term “dysphemia”, the ROR was 7.3 (95% CI: 5.4–9.8). With the Lower Level Term “stuttering”, 584 cases were registered in the database of which 17 involved MPH. The ROR was 13.9 (95% CI: 8.6–22.5). This study found a signal for stuttering with MPH.
- 16 August 2019
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 85 (11) , 2634-2637
Open AccessMethylphenidate and stuttering
Methylphenidate (MPH) is a piperidine similar to amphetamines, and is indicated for attention deficit hyperactivity disorder. Studies concerning stuttering occurring with MPH are contradictory. We investigated the association between MPH and stuttering. We analysed reports in the World Health Organization global individual case safety reports database, Vigibase, up to 31 December 2018, with the MedDRA preferred term “dysphemia” and the lower level terms “stutter” and “stuttering”. The association between exposure to MPH and occurrence of the adverse drug reaction was estimated by disproportionality analysis. Reporting odds ratios (RORs) were calculated with 95% confidence intervals (CIs). In total, 2975 cases of dysphemia were reported, of which 46 reports were associated with MPH. For the Preferred Term “dysphemia”, the ROR was 7.3 (95% CI: 5.4–9.8). With the Lower Level Term “stuttering”, 584 cases were registered in the database of which 17 involved MPH. The ROR was 13.9 (95% CI: 8.6–22.5). This study found a signal for stuttering with MPH.
- 1 February 2019
- Published by Elsevier in Revue D'Épidémiologie Et de Santé Publique
- Vol. 67 (1) , 69
Impact pronostique de la concentration de 3-hydroxymyristate sur la survie des patients atteints de cirrhose alcoolique ou virale
- 1 February 2019
- Published by Elsevier in Revue D'Épidémiologie Et de Santé Publique
- Vol. 67 (1) , 69
Impact pronostique de la concentration de 3-hydroxymyristate sur la survie des patients atteints de cirrhose alcoolique ou virale